Mylan, Pfizer provide update regarding proposed combination of Mylan and Upjohn

HERTFORDSHIRE, England and PITTSBURGH and NEW YORK, March 26, 2020 (PRNewswire) — Mylan N.V. and Pfizer Inc. on Thursday announced that due to the unprecedented circumstances surrounding the COVID-19 pandemic, including associated delays in the regulatory review process, the proposed transaction involving Mylan and Upjohn, a division of Pfizer, is now anticipated to close in the second half of 2020.

There are no additional changes to the previously announced terms or plans regarding the transaction. The two companies remain highly confident in the benefits of the pending transaction to their respective shareholders and other stakeholders. Mylan, Pfizer and Upjohn are working closely on integration planning and are making significant progress toward Day 1 readiness. Together the companies continue to progress toward a successful close.

The primary focus of both companies remains the health and safety of their dedicated and valued employees who are working tirelessly towards completion of this transaction while also maintaining their responsibility to meet patient needs during this extraordinary time.

Mylan and Pfizer continue to look forward to the proposed combination creating a new champion for global health at the close of this transaction.